Abstract:Real-world data on the management of patients with primary biliary cholangitis (PBC) are so far scarce in Germany. Therefore, we aimed to establish a nationwide registry and describe the clinical characteristics and therapy of PBC patients. Three different cohorts defined as ursodeoxycholic acid (UDCA) responders, as inadequate responders according to Paris II criteria, and as newly diagnosed patients were prospectively recruited. This manuscript includes the baseline data of the project. In total, 33/77 (43%) contacted centres (58% of university hospitals, 38% of non-university hospitals, and 24% of private practices) recruited 515 patients including 204 UDCA responders, 221 inadequate responders to UDCA, and 90 newly diagnosed patients. All patients were treated with UDCA; however, a UDCA dosage below the recommended dosage of 13 mg/kg/d was observed in 38.5% of individuals after 12 months of treatment. UDCA dosages were lower in nonacademic compared to academic centres. Only 75/219 (38.5%) of inadequate responders to UDCA received a second-line therapy with obeticholic acid (OCA) and/or bezafibrate (BZF). OCA (13% vs. 4.5%) and BZF (14% vs. 6.5%) were significantly more often prescribed by academic vs. nonacademic centres. Pruritus (27% vs. 15.5%), fatigue (23% vs. 4.5%), and sicca syndrome (14% vs. 1%) were significantly more often reported by academic centres. The German PBC registry could be established, which indicates suboptimal therapy in a relevant proportion of patients and shows significant differences between academic and nonacademic centres. Results are fundamental to improving clinical management at different levels of care. Es gibt bislang wenige Real-World-Daten zur Primär Biliären Cholangitis (PBC) in Deutschland. Es war daher das Ziel, ein nationales Register zu gründen, um klinische Charakteristika von Patienten mit PBC und deren medikamentöse Therapie zu beschreiben. Es wurden drei Subgruppen innerhalb des Registers definiert: Patienten mit adäquatem Ansprechen auf Ursodeoxycholsäure (UDCA) nach den Paris-II-Kriterien, Patienten mit inadäquatem Therapieansprechen und neu diagnostizierte Patienten. Im vorliegenden Manuskript werden die Patientencharakteristika zum Rekrutierungszeitpunkt in das Register beschrieben. 33/77 (43%) kontaktierten Zentren (58% der Universitätskrankenhäuser, 38% der nicht-universitären Krankenhäuser, 24% der Praxen) rekrutierten 515 Patienten (204 UDCA Responder, 221 inadäquate UDCA-Responder, 90 neu diagnostizierte Patienten). Alle Patienten wurden mit UDCA behandelt, allerdings wurde bei 38,5% der Fälle eine Dosis niedriger als die empfohlene Dosierung von 13 mg/kg/d nach 12 Monaten Therapie beobachtet. Die UDCA-Dosis war an nicht-akademischen Zentren niedriger als an akademischen Zentren. Nur 75/219 (38.5%) Patienten mit inadäquatem UDCA-Therapieansprechen erhielten eine Behandlung mit Obeticholsäure (OCA) oder Bezafibrat (BZF). OCA (13% vs. 4,5%) und BZF (14% vs. 6,5%) wurden signifikant häufiger von akademischen Zentren verordnet. Pruritus (27% vs. 15,5%), Müdigkeit (23% vs. 4,5%) und ein Sicca-Syndrom (14% vs. 1%) wurden signifikant häufiger an akademischen Zentren beschrieben. Das Deutsche PBC-Register konnte erfolgreich gegründet werden, weist auf eine sub-optimale Therapie bei vielen Patienten hin und zeigt signifikante Unterschiede zwischen akademischen und nicht-akademischen Zentren. Die Ergebnisse sind wichtig, um die Versorgung von PBC-Patienten zu verbessern. Received: 16 April 2024 Accepted after revision: 02 August 2024 Article published online: 03 September 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Diagnostik- und Therapieleitfaden 2023 für PBC in Österreich

Sub-optimal therapy of patients with primary biliary cholangitis (PBC) in the real-life stetting of the German PBC cohort

[Primary biliary cholangitis-response criteria of first-line treatment and perspectives of second-line therapy]

Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid

Clinical Analysis of Primary Biliary Cirrhosis: a Report of 31 Cases

Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape

New Therapies for Primary Biliary Cirrhosis

[Primary sclerosing cholangitis-Diagnosis and treatment 2024]

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

A209 EXPERT CONSENSUS CRITERIA AND PRACTICAL RECOMMENDATIONS FOR PBC CARE IN THE COVID-19 ERA AND BEYOND

Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis

Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators

New Treatment Paradigms in Primary Biliary Cholangitis

Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis

Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool

Pretransplant Evaluation and Liver Transplantation Outcome in PBC Patients